Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. - Wikidata - awgldk - TriplyDB

Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.

Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.

http://www.wikidata.org/entity/Q33391550

about

Update on rational targeted therapy in AML Beyond hypomethylating agents failure in patients with myelodysplastic syndromes Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment Antifungal application of nonantifungal drugs Microfluidic chemical cytometry of peptide degradation in single drug-treated acute myeloid leukemia cells.Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.Emerging therapies for acute myeloid leukemia.Current therapy of myelodysplastic syndromes Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.The aminopeptidase inhibitor CHR-2863 is an orally bioavailable inhibitor of murine malaria.Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial.Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia.Novel therapies for children with acute myeloid leukaemia.Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia.Positioning of aminopeptidase inhibitors in next generation cancer therapy.Targeted therapy of acute myeloid leukemia.Single-cell proteomics: potential implications for cancer diagnostics.The safety of treatment options for elderly people with acute myeloid leukemia.M1 aminopeptidases as drug targets: broad applications or therapeutic niche?The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR.New treatments and strategies in acute myeloid leukemia.Increased CD13 Expression in Acute Myeloid Leukemia-associated Early Acute Hypoxic Respiratory Failure.5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.

P2860

Q26766152-B038CF47-FAF9-4035-BBB6-884207F19A21 Q26827079-98C5A90B-AE17-49FB-BC6C-4971B9505DE6 Q28486349-3F191C1B-96B6-402B-9F7B-E6A9D9795FEE Q30433553-3057A2CC-204D-4F95-9138-071F821C4224 Q30540276-70F30DE4-9814-431E-9336-32CD4A34A82F Q33406190-DCDA0669-DF95-47F8-9B2D-E23831458F5D Q33576363-41BA8D75-6167-45E2-9E19-9C25083AE7BE Q34013796-5F81169F-DA28-4BFC-B91F-2A5B2A6E8925 Q35546759-F25F9CCC-2981-467B-AD41-CACB4E152CBD Q36018855-5D27E67E-DCA9-4417-9BEC-4CCC79770879 Q38003665-FBA89FBE-5BC6-40C8-AFC9-454974AD556A Q38042705-5AC054C2-5B2E-482E-BC12-44187ABA3200 Q38096798-67EAB110-3E59-4594-94D2-7EECD97EA735 Q38161965-F36D5823-20B8-4D7B-8186-072EEE220A3B Q38169200-D2927976-E30E-4633-A10B-C4D55997FF05 Q38175346-649F089E-E273-4845-942E-E4AEE81958B2 Q38333251-079DA59D-9F9B-46A7-986F-4AD03FE6FFBD Q38741203-F8BAC89F-6097-4C37-A0EE-91E9C2DF3E55 Q38760822-8E06050A-A523-4D44-97FA-A9FDA67A33E3 Q39079405-84E7C602-6490-4B62-8386-3D12DFB13FB6 Q39113061-C787AB4F-26E1-468C-A972-DC72A6E5CD2D Q41860750-59287624-780B-4CC8-A0BB-0A3A24AC8F60 Q41881090-D5F9A080-1F60-4D0C-9F65-D4FA4EFA6F49 Q47944104-F9A24DBB-89C6-4BE2-B700-C9287B9811C8 Q51039721-D5AEFB85-F384-4010-AF11-3BB3FC6B126D

P2860

Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.

http://www.wikidata.org/entity/Q33391550

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Phase I/II clinical study of T ...... d leukemia and myelodysplasia.

@ast

Phase I/II clinical study of T ...... d leukemia and myelodysplasia.

@en

type

label

Phase I/II clinical study of T ...... d leukemia and myelodysplasia.

@ast

Phase I/II clinical study of T ...... d leukemia and myelodysplasia.

@en

prefLabel

Phase I/II clinical study of T ...... d leukemia and myelodysplasia.

@ast

Phase I/II clinical study of T ...... d leukemia and myelodysplasia.

@en

P1433

Q33391550-8A36419B-2402-4920-BB8F-063B8035DF87

P1476

Q33391550-5A7BA2C4-5F8B-4A8B-A546-7DF211571B52

P2093

Q33391550-04126D28-2EF7-4703-9C3A-31B10F9A792A

Q33391550-15715046-25F5-4AF4-A6C6-C6C828E70622

Q33391550-4BF83C52-F735-4ACD-B783-FB92443DD1DA

Q33391550-4ED5C30D-0FAA-48CE-A3A0-FB7C79B82F26

Q33391550-52CFCD08-CF29-4678-A186-DC3057FE0142

Q33391550-A392A95B-EC66-4BC1-846D-039B0D6178AB

Q33391550-A9EF2BF4-B717-4399-B15A-DF210AD9B0B5

Q33391550-AE0C1C32-581F-4E2A-AC92-B898DDF79C32

Q33391550-B2D5AA10-802D-445C-A991-3533D9D98B7D

Q33391550-B48715BE-ED75-4240-AB56-3DAE3B927FB2

P304

Q33391550-F03FD54A-F9E7-428E-AEAE-40C6517FF38D

P31

Q33391550-12817E5E-E83B-440F-85C9-FB9E0D2AD738

P356

Q33391550-55DCAEAB-EC6B-4597-B770-06FD190A4567

P407

Q33391550-DBDE5E46-5AD4-4471-8E27-168151F88411

P433

Q33391550-7F3552DB-F86F-4775-A979-625BFA195FBE

P478

Q33391550-E33A8547-B06A-4005-9C02-E1A4265FD1F5

P50

Q33391550-0CC2EC82-6858-41BE-8897-C1CFA14712B8

Q33391550-30487DCD-F145-4DDB-B622-FB3928C0C871

Q33391550-6D46A625-2A9C-4F51-9286-F27C6583523C

Q33391550-BB552596-E611-4CA4-9C38-08D74C9DE722

Q33391550-CE541D0F-AA6E-4F49-BA82-9A9817DCBADA

P577

Q33391550-99422CF2-1A47-4F6A-B38F-61CAFDEFD7A5

P5875

Q33391550-B59AC3EB-614E-4394-9016-5324079BEC92

P698

Q33391550-FAA5D06A-5534-4B21-9922-B4444375E816

P921

Q33391550-34627147-CB9C-4B72-9B10-E0466D9F23C5

P356

JCO.2009.27.6295

P1433

Journal of Clinical Oncology

P1476

Phase I/II clinical study of T ...... d leukemia and myelodysplasia.

@en

P2093

Alan K Burnett

http://www.w3.org/2001/XMLSchema#string

Alison F Richardson

http://www.w3.org/2001/XMLSchema#string

Chris Jenkins

http://www.w3.org/2001/XMLSchema#string

Elisabeth Bone

http://www.w3.org/2001/XMLSchema#string

Faith Davies

http://www.w3.org/2001/XMLSchema#string

Gareth Morgan

http://www.w3.org/2001/XMLSchema#string

Gert J Ossenkoppele

http://www.w3.org/2001/XMLSchema#string

Leon Hooftman

http://www.w3.org/2001/XMLSchema#string

Nicolas Flores

http://www.w3.org/2001/XMLSchema#string

Sonja Zweegman

http://www.w3.org/2001/XMLSchema#string

P304

4333-4338

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.27.6295

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Carsten Müller-Tidow

Pieter Sonneveld

P577

2010-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45821214

http://www.w3.org/2001/XMLSchema#string

P698

20733120

http://www.w3.org/2001/XMLSchema#string

P921